Genesys Capital invests in and builds companies in the high-growth sectors of life sciences. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies.
Employees: 1-10
Portfolio 22
| Date | Name | Website | Total Raised | Location |
| 01.11.2024 | Feldan | feldan.com | $16.5M | Canada, On... |
| 27.10.2023 | Cryostasis... | cryostasis.ca | - | Canada |
| 27.10.2023 | giiant pha... | giiant.com | $11M | Canada, Mo... |
| 02.06.2022 | Fusion Pha... | fusionpharma.com | $195.91M | Canada, On... |
| 30.01.2022 | Questat In... | questat.ca | - | - |
| 30.01.2022 | Veralox Th... | veralox.com | $22M | - |
| - | Inversago ... | inversago.com | $137M | - |
| - | Ionalytics... | thermo.com | - | United Sta... |
| - | Debiopharm | debiopharm.com | - | Switzerlan... |
| - | Adapsyn Bi... | adapsyn.com | - | - |
Show more
Persons 6
| Date | First Name | Last Name | Title | Location | |||
| - | Paras | Sharma | Senior Ass... | - | - | - | |
| - | Kelly | Holman | Co-founder... | - | - | - | |
| - | Damian | Lamb | Co-founder... | - | - | - | |
| - | Jamie | Stiff | Managing D... | - | - | - | |
| - | Christine | Thoburn | Office Man... | - | - | - | |
| - | Sarah | Farr | Senior Ass... | - | - | - |
Mentions in press and media 8
| Date | Title | Description |
| 13.06.2025 | The Rise of Canadian Life Sciences: A New Era of Innovation and Investment | In the heart of Canada, a revolution is brewing. The life sciences sector is experiencing a surge, fueled by innovative companies and strategic investments. Two recent announcements highlight this trend: Genesys Capital's closing of its lar... |
| 11.06.2025 | Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP | TORONTO & MONTREAL–(BUSINESS WIRE)–June 11, 2025– Genesys Capital (“Genesys”) is pleased to announce the upcoming closing of Genesys Ventures IV LP (“Fund IV” or the “fund”) to continue its successful track record of building Canadian l... |
| 06.03.2020 | Aortyx cierra una ronda de €650.000 liderada por Genesis Ventures | 06/03/2020 Nota de prensa AORTYX CIERRA UNA RONDA DE €650.000 LIDERADA POR GENESIS VENTURES. Aortyx, ‘spin-off’ del IQS especializada en la creación de dispositivos endovasculares para las disecciones aórticas, ha ampliado capital en 650... |
| 24.08.2016 | Genesys Capital closes $90 million of its $125 million target for third fund | Toronto-based Genesys Capital, which is focused on investing in seed healthcare startups, announced that it’s closed $90 million of its $125 million target for its third fund, according to PE Hub. Managing director Damian Lamb said that it ... |
| 17.12.2012 | Naurex Raises $38M in Series B Financing | Naurex Inc., an Evanston, Illinois-based clinical-stage company focused on psychiatry and neurology, has raised $38m in Series B financing. The round was led by new investor Baxter Ventures, with participation from new investor Savitr Capit... |
| - | Fusion Pharmaceuticals Raises $105 Million In Oversubscribed Series B Financing | Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investo... |
| - | Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics | HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Se... |
| - | Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments | HAMILTON ONTARIO, February 23, 2017 – Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing... |